Safety and Efficacy Profile of Commercial Veterinary Vaccines against Rift Valley Fever: A Review Study.
Rift Valley Fever (RVF) is an infectious illness with serious clinical manifestations and health consequences in humans as well as a wide range of domestic ruminants. This review provides significant information about the prevention options of RVF along with the safety-efficacy profile of commercial vaccines and some of RVF vaccination strategies. Information presented in this paper was obtained through a systematic investigation of published data about RVF vaccines. Like other viral diseases, the prevention of RVF relies heavily on immunization of susceptible herds with safe and cost-effective vaccine that is able to confer long-term protective immunity. Several strains of RVF vaccines have been developed and are available in commercial production including Formalin-Inactivated vaccine, live attenuated Smithburn vaccine, and the most recent Clone13. Although Formalin-Inactivated vaccine and live attenuated Smithburn vaccine are immunogenic and widely used in prevention programs, they proved to be accompanied by significant concerns. Despite Clone13 vaccine being suggested as safe in pregnant ewes and as highly immunogenic along with its potential for differentiating infected from vaccinated animals (DIVA), a recent study raised concerns about the safety of the vaccine during the first trimester of gestation. Accordingly, RVF vaccines that are currently available in the market to a significant extent do not fulfill the requirements of safety, potency, and DIVA. These adverse effects stressed the need for developing new vaccines with an excellent safety profile to bridge the gap in safety and immunity. Bringing RVF vaccine candidates to local markets besides the absence of validated serological test for DIVA remain the major challenges of RVF control.
Campaign for Control of RVF Disease, Ministry of Agriculture, Gizan City, Saudi Arabia.
Moataz
0000-0001-9435-0148
M
Alhaj
Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):73-4
20682909
Clin Microbiol Rev. 2007 Jul;20(3):489-510, table of contents
17630337
Br J Exp Pathol. 1949 Feb;30(1):1-16
18128091
Vaccine. 2009 Nov 5;27 Suppl 4:D69-72
19837291
Vet Res. 2004 Jul-Aug;35(4):425-43
15236675
Virol J. 2011 Dec 12;8:532
22152149
J Virol. 2001 Feb;75(3):1371-7
11152510
Front Cell Infect Microbiol. 2012 Oct 26;2:131
23112960
J Med Virol. 2006 Jun;78(6):787-91
16628582
Arch Virol. 1984;80(2-3):103-17
6326708
J S Afr Vet Assoc. 1977 Mar;48(1):45-8
874947
PLoS Negl Trop Dis. 2016 Mar 31;10(3):e0004550
27031621
Vaccine. 2011 Apr 12;29(17):3222-9
21354483
J Virol Methods. 2013 Nov;193(2):426-31
23850696
Am J Trop Med Hyg. 1995 Oct;53(4):405-11
7485695
J S Afr Vet Assoc. 1979 Sep;50(3):155-7
551199
Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):52-7
20682906
J Virol. 2008 Mar;82(6):2681-91
18199647
Virol J. 2009 Jul 06;6:94
19580675
Vaccine. 2010 Jun 23;28(29):4581-7
20470792
J Immunol. 1964 Aug;93:293-9
14202259
Onderstepoort J Vet Res. 2015 May 29;82(1):857
26244679
Vaccine. 2012 Oct 12;30(46):6534-40
22947138
J Virol Methods. 2003 Nov;113(2):103-12
14553896
Emerg Infect Dis. 2011 Sep;17(9):e1
21888781
Rev Sci Tech. 1995 Dec;14(4):979-89
8639966
Vaccine. 1999 Aug 20;18(1-2):181-9
10501248
Int J Antimicrob Agents. 2003 Feb;21(2):153-7
12615379
Dev Biol (Basel). 2004;119:15-29
15742615
Curr Opin Virol. 2012 Jun;2(3):315-23
22463980
Sci Rep. 2016 Feb 05;6:20617
26847478
Clin Vaccine Immunol. 2010 Dec;17(12):1842-9
20876822